Certara (NASDAQ:CERT) Stock Price Up 8.8% on Analyst Upgrade

Certara, Inc. (NASDAQ:CERT) traded up 8.8% on Monday after Robert W. Baird raised their price target on the stock from $9.00 to $13.00. Robert W. Baird currently has a neutral rating on the stock. Certara traded as high as $14.15 and last traded at $14.05. 905,668 shares traded hands during trading, a decline of 20% from the average session volume of 1,138,576 shares. The stock had previously closed at $12.91.

Several other research analysts also recently commented on CERT. Barclays decreased their price target on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Stephens reiterated an “overweight” rating and issued a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. TD Cowen assumed coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target for the company. Finally, William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Institutional Investors Weigh In On Certara

A number of large investors have recently added to or reduced their stakes in CERT. Kopion Asset Management LLC raised its stake in shares of Certara by 46.0% during the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after acquiring an additional 175,005 shares during the last quarter. Principal Financial Group Inc. raised its position in Certara by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock valued at $5,660,000 after purchasing an additional 15,739 shares during the last quarter. Vontobel Holding Ltd. bought a new position in Certara during the 4th quarter valued at approximately $1,295,000. Barclays PLC lifted its holdings in Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company’s stock worth $825,000 after buying an additional 46,880 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in shares of Certara in the 4th quarter worth approximately $148,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Down 3.6 %

The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market capitalization of $2.24 billion, a PE ratio of -69.40, a PEG ratio of 9.29 and a beta of 1.64. The company has a 50 day moving average price of $11.62 and a 200-day moving average price of $11.41.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.